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Abstract
Background: Identification of broad neutralization epitopes in HIV-1 envelope spikes is paramount for HIV-1
vaccine development. A few broad neutralization epitopes identified so far are present on the surface of native
HIV-1 envelope spikes whose recognition by antibodies does not depend on conformational changes of the
envelope spikes. However, HIV-1 envelope spikes also contain transiently-exposed neutralization epitopes, which
are more difficult to identify.
Results: In this study, we constructed single chain Fvs (scFvs) derived from seven human monoclonal antibodies
and genetically linked them with or without a glycosyl-phosphatidylinositol (GPI) attachment signal. We show that
with a GPI attachment signal the scFvs are targeted to lipid rafts of plasma membranes. In addition, we
demonstrate that four of the GPI-anchored scFvs, but not their secreted counterparts, neutralize HIV-1 with various
degrees of breadth and potency. Among them, GPI-anchored scFv (X5) exhibits extremely potent and broad
neutralization activity against multiple clades of HIV-1 strains tested. Moreover, we show that GPI-anchored scFv
(4E10) also exhibited more potent neutralization activity than its secretory counterpart. Finally, we demonstrate that
expression of GPI-anchored scFv (X5) in the lipid raft of plasma membrane of human CD4
+ T cells confers long-
term resistance to HIV-1 infection, HIV-1 envelope-mediated cell-cell fusion, and the infection of HIV-1 captured and
transferred by human DCs.
Conclusions: Thus GPI-anchored scFv could be used as a general and effective way to identify antibodies that
react with transiently-exposed neutralization epitopes in envelope proteins of HIV-1 and other enveloped viruses.
The GPI-anchored scFv (X5), because of its breadth and potency, should have a great potential to be developed
into anti-viral agent for HIV-1 prevention and therapy.
Background
Human Immunodeficiency Virus type 1 (HIV-1) envel-
ope spike is a trimeric complex consisting of three non-
covalently linked heterodimers of gp120 and gp41.
Gp120, an exterior glycoprotein, mediates cell attach-
ment, receptor and co-receptor binding. Gp41, a trans-
membrane glycoprotein, mediates viral and cell
membrane fusion, which is critical for viral core to
enter target cells. Both gp120 and gp41 are derived by
cleavage of a common precursor gp160.
HIV-1 envelope spike also elicits antibody responses.
Neutralizing antibodies block viral entry by recognizing
epitopes on the envelope spike critical for its attachment,
receptor and co-receptor interaction, or fusion and
appear to be an important component of a protective
immune response [1]. However, antibodies that can neu-
tralize a broad range of primary HIV-1 isolates have been
extremely difficult to generate [2]. Despite more than
two decades of effort, only a few broadly neutralizing
antibodies (2G12, b12, VRC001, VRC002, VRC003, PG9,
PG16, 2F5 and 4E10/Z13) have been identified through
screening antibody libraries or memory B cells from
HIV-1 infected individuals [3-13]. Unfortunately, many
efforts to elicit such antibody responses by active immu-
nization have not been successful [14]. Interestingly,
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broadly neutralizing antibodies are present on the surface
of the native spike and their recognition by the antibodies
does not depend on conformational changes of envelope
proteins.
Upon interaction with CD4 receptor, a lipid raft-
associated protein [15-18], on the target cell surface,
t h en a t i v eH I V - 1e n v e l o p espike goes through exten-
sive conformational changes that allow additional bind-
ing to a co-receptor, CXCR4 for T-cell tropic strains
or CCR5 for macrophage-tropic isolates. Co-receptor
binding results in further conformational changes and
leads to the insertion of the fusion peptide in gp41
into target cell membrane tod r i v et h es u b s e q u e n t
fusion event. During these conformational changes
epitopes that are hidden from or not totally exposed
on the surface of native spike are transiently exposed
and become accessible to antibodies specific for these
transiently-exposed epitopes. Likely, some of these
epitopes are also neutralization epitopes. Based on this
assumption, several groups reported using gp120-CD4
or gp120-CD4-CCR5 complex as immunogens to elicit
antibodies that react with transiently-exposed neutrali-
zation epitopes or as selecting antigens for screening
human phage display antibody libraries [19-21]. It was
hypothesized that in these complexes HIV-1 envelope
may stabilize some of the transiently-exposed epitopes
so that antibodies present in the libraries that recog-
nized these stabilized epitopes can be selected [22].
One notable example was the identification of a CD4-
inducible antibody X5 in a phage display Fab antibody
library with a gp120-CD4-CCR5 complex [21].
Previously, we unexpectedly found that by genetically
linking the scFv of an anti-HIV-1 human antibody
(TG15) to the transmembrane domain of subunit one of
the type 1 interferon receptor, the cell-surface expressed
scFv, but not its secretory form, we markedly inhibited
HIV-1 entry and HIV-1 envelope-mediated cell-cell
fusion [23,24]. The antibody recognizes the cluster II
determinant (amino acid residues 644-663) which resides
within the second heptad repeat (HR2) of HIV-1 gp41
[25]. HIV-1 gp41 mediated fusion is triggered by interac-
tion between the second and the first heptad repeats,
which converts a prehairpin gp41 trimer into a fusogenic
three-hairpin bundle [26]. Similarly, it was reported that
expressing a peptide derived from the HR2 domain on
the surface of HIV-1-susceptible cells exhibits greater
inhibitory effect on HIV-1 [27] and such an inhibition is
achieved by capturing a gp41 fusion intermediate by the
cell-surface expressed peptide prior to viral and cell
membrane fusion [28]. Thus, it is clear that the cell-
surface expressed scFv or peptide that recognizes or is
derived from the HR2 domain can capture transiently-
exposed epitopes in entry fusion intermediates. However,
it is not clear whether transiently-exposed epitopes on
HIV-1 envelope spikes other than that resides in the HR2
domain can also be captured by cell-surface expressed
scFvs.
In nature, over 200 cell surface proteins with various
f u n c t i o n sa r ea n c h o r e dt ot h ep l a s m am e m b r a n eb ya
covalently attached glycosyl-phosphatidylinositol (GPI)
anchor [29]. Many GPI-anchored proteins are targeted
into the lipid rafts of the plasma membrane. These spe-
cialized dynamic micro-domains are rich in cholesterol,
sphingolipids and glycerophospholipids [30]. The lipid
raft has been known to be a gateway for HIV-1 budding
[31]. Furthermore, involvement of lipid rafts in HIV-1
entry into T cells and macrophages has also been pro-
posed [15,31-33].
We therefore hypothesized that if one can express
antibodies that react with transiently-exposed neutraliza-
tion epitopes in a GPI anchored form and a GPI anchor
can target these antibodies into the lipid rafts of plasma
membranes of HIV-1-susceptible cells, these antibodies
should neutralize infection. If correct, we predict that
when the HIV-1 native spike interacts with the CD4
receptor, triggering a series of conformational changes,
the transiently-exposed neutralization epitopes will be
captured by GPI-anchored antibodies residing in the
same lipid raft of the plasma membrane.
To test this hypothesis in this study, we constructed
scFvs derived from seven different human monoclonal
antibodies AB31, AB32, TG15, 4E10, 48d, X5 and AB65.
AB65 recognizes the influenza hemagglutinin used here
as negative control (Zhou, et al. data not shown). AB31
and AB32 are high affinity antibodies. AB31 recognizes
cluster III determinant of gp41 and AB32 interacts with
gp120, but its epitope is not well characterized [34]. Anti-
body (TG15) recognizes the cluster II determinant
(amino acid residues 644-663) which resides within the
second heptad repeat (HR2) of HIV-1 gp41 [23]. Antibo-
dies 48d and X5 recognize distinct, but partially over-
lapped CD4 induced epitopes that are located close to
both co-receptor-binding and CD4-binding sites of gp120
[21,35,36]. Antibody 4E10 that recognizes a linear epitope
residing in the membrane proximate region of gp41 is a
neutralizing antibody [7]. Here, we show that by geneti-
cally linking the scFvs with a GPI attachment signal
derived from decay accelerating factor (DAF) [37] the
scFvs are targeted to lipid rafts of plasma membranes. In
addition, we demonstrate that the four of these GPI-
anchored scFvs (X5, 48d, AB32 and TG15), but not their
secretory counterparts, neutralize HIV-1 with various
degrees of breadth and potency. Among them, GPI-
anchored scFv (X5) exhibits extremely potent and broad
neutralization activity against multiple clades of HIV-1
strains tested. Moreover, we show that GPI-anchored
scFv (4E10) also exhibited more potent neutralization
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strate that expression of GPI-anchored scFv (X5) in the
lipid raft of plasma membrane of human CD4
+ T cells
confers long-term resistance to HIV-1 infection, HIV-1
envelope-mediated cell-cell fusion and the infection of
HIV-1 captured and transferred by human DCs. Thus,
we conclude that GPI-anchored scFv is an effective way
to capture transiently-exposed neutralization epitopes in
the HIV-1 envelope spike.
Results
Expression of scFv in the lipid raft of plasma membrane
through a GPI anchor
To generate GPI-anchored and secretory scFvs, the
sequences encoding scFvs derived from seven different
human antibodies AB31, AB32, TG15, 4E10, 48d, X5
and AB65 were genetically linked with the sequence
encoding a his-tagged IgG3 hinge region and with or
without the sequence encoding a GPI attachment signal
of DAF [37]. The fusion genes scFv/IgG3 hinge/his-tag/
DAF and scFv/IgG3 hinge/his-tag were inserted into a
third generation lentiviral vector pRRL (Figure 1A). The
recombinant viruses were then generated as described
before [38] and used to transduce TZM.bl cells and
human CD4
+ T cells CEMss and CEMss-CCR5 (see
below). The expression of transgenes and localization of
transgene products in the transduced cells were carefully
studied.
Figure 1B shows the expression of scFvs/hinge/his-tag/
DAF and scFvs/hinge/his-tag in cell lysates and culture
supernatants of transduced TZM.bl cells by western blot
using anti-his-tag and anti-tubulin antibodies. As
expected, without a GPI attachment signal, all scFvs
were detected in both culture supernatants and cell
lysates with a majority in supernatants (the right panel).
By contrast, all scFvs with a GPI attachment signal were
only detected in cell lysates, but not in culture superna-
tants (the left panel). These data indicate that inclusion
of a GPI attachment signal prevents secretion of the
scFvs.
To determine if scFvs/hinge/his-tag/DAF were
expressed on the cell surface through a GPI anchor,
scFv/hinge/his-tag/DAF-transduced TZM.bl cells were
treated with or without phosphatidylinositol-specific
phospholipase C (PI-PLC) and stained with anti-his-tag
antibody followed by FACS analysis. As a control, cells
transduced with previously reported m-scFv (TG15), a
cell-surface expressed scFv (TG15) with a conventional
transmembrane domain [23] went through the same PI-
PLC treatment and staining processes. Figure 1C shows
that all scFv/hinge/his-tag/DAFs express highly on cell
surface (about 10-fold higher than that of m-scFv) and
t h ee x p r e s s i o nw e r es u b s t a n tially reduced with PI-PLC
treatment. In contrast, no reduction in cell surface
expression of scFv was observed in m-scFv-transduced
cells, indicating that the expression of scFv/hinge/his-
tag/DAF on the cell surface is indeed through a GPI
anchor. In addition, cell surface expression of GPI-
anchored scFv (4E10) along with GPI-anchored scFvs
(AB65 and X5) was also analyzed by immune staining
and FACS analysis. Additional File 1 shows that cell sur-
face expression of GPI-anchored scFv (4E10) is similar
to those GPI-anchored scFvs (AB65 and X5). Thus, for
the sake of simplicity in the remaining text we will refer
the scFv/hinge/his-tag/DAF as GPI-scFv and scFv/hinge/
his-tag as secretory scFv.
To determine if GPI-scFvs are located in the lipid rafts
of plasma membranes, mock- and GPI-scFv (AB65 and
X5)-transduced TZM.bl cells were seeded into wells of
cover slip chambers and cultured overnight. Cells were
then fixed with 4% formaldehyde and co-stained with 1)
m o u s ea n t i - h i s - t a ga n t i b o d yf o l l o w e db yA l e x a4 8 8 -
conjugated goat anti-mouse IgG antibody; 2) Alexa 555-
conjugated cholera toxin subunit B (CtxB); and 3)
DAPI. CtxB interacts with GM1 (a lipid raft marker) on
the cell surface. Figure 2 shows that both GPI-scFvs
(AB65 and X5) are co-localized with GM1 on cell sur-
face, implying that they are located in the lipid raft of
the plasma membrane.
GPI-scFv (X5) exhibits remarkable degree of breadth and
potency against HIV-1
Next, we compared CD4, CCR5 and CXCR4 expression
in the secretory and GPI-scFv-transduced TZM.bl cells
and found that there is no significant difference in their
expression compared to mock-transduced TZM.bl cells,
suggesting that the expression of transgenes does not
alter the expression of the receptor and the coreceptors
for HIV-1 in the transduced cells (Additional File 2).
Neither did we find that the expression of the trans-
genes alters the cell growth (Zhou et al.d a t an o t
shown).
To test neutralization activity of the secretory versus
the GPI-scFvs against HIV-1, an eleven multiclade HIV-
1 pseudotype panel and a retroviral envelope 10A1
pseudotype were used to infect transduced TZM.bl cells
in a single-round infection experiment [23]. The retro-
viral envelope 10A1 recognizes either Ram-1 or Glvr-1
as a receptor for cell entry [39] and used here as nega-
tive control. The eleven HIV-1 pseudotypes consist of
HIV-1 envelopes derived from clade A (Q168), clade B
(HxBc2, JF-RL, ADA, AD8, Yu2 and consensus B), clade
B’ (CNE11), clade C (Mj4 and CNE17) and clade E
(CNE8). Figure 3 shows mean and standard deviation of
relative luciferase activity (RLA) in mock-, secretory and
GPI-scFv-transduced cells infected with these pseudo-
types. Compared to mock-transduced cells, cells trans-
duced with all secretory and GPI-anchored scFvs did
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pseudotypes control (Figure 3A and 3B). Compared to
mock-transduced cells, cells transduced with secretory
scFvs (AB65, AB31, AB32, TG15, and 48d) did not
show significant neutralization activity against any of
these HIV-1 pseudotypes tested. Cells transduced with
secretory scFv (X5) showed low degree of neutralization
activity against 3 of 11 HIV-1 pseudotypes (ADA, Con-
sensus B and Mj4). In contrast, cells transduced with
secretory scFv (4E10) exhibited more than 50% neutrali-
zation activity against all 11 HIV-1 pseudotypes tested
(Figure 3B). Compared to mock-transduced cells, cells
Figure 1 Expression of secretory and GPI-anchored scFvs in transduced TZM.bl cells. A. Schematic diagram of the lentiviral vectors pRRL-
scFv/hinge/his-tag/DAF and pRRL-scFv/hinge/his-tag. Single chain Fvs (scFvs) were derived from seven human monoclonal antibodies AB31,
AB32, TG15, 48d, X5 and AB65; hinge: a human IgG3 hinge region; his-tag: a 6 histidine residue tag; DAF: the C-terminal 34 amino acid residues
of decay accelerating factor. B. Western blot analysis of expression of scFvs (AB31, AB32, TG15, 48d, X5 and AB65) in TZM.bl cells transduced with
lentiviral vectors pRRL-scFv/hinge/his-tag/DAF and pRRL-scFv/hinge/his-tag. GPI-scFv: GPI-anchored scFv; Sec-scFv: secretory scFv; anti-his: anti-
his-tag antibody. C. FACS analysis of cell surface expression of scFv/hinge/histag/DAF in mock-, scFvs (AB31, AB32, TG15, 48d, X5 and AB65)/
hinge/histag/DAF- or m-scFv(TG15)-transduced TZM.bl cells with or without PI-PLC treatment.
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potency and breadth against HIV-1 pseudotypes (Figure
3A). Like cells transduced with GPI-scFvs (AB65) con-
trol, cells transduced with GPI-scFvs (AB31) did not
show neutralization breadth and potency against any of
these pseudotypes tested. Cells transduced with GPI-
scFv (AB32) neutralized 2 of 11 HIV-1 pseudotypes (JR-
FL and Consensus B) with low degree of potency. Cells
transduced with GPI-scFv (TG15) neutralized 8 of 11
HIV-1 pseudoviruses expressing envelopes derived from
clades A, B and B’ with various degree of potency, but
n o tc l a d e sCa n dE .C e l l st r a n s d u c e dw i t hG P I - s c F v
(4E10) neutralized all 11 HIV-1 pseudotypes with
increased potency (more than 90% neutralization activ-
ity) as compared to cells transduced with secretory scFv
(4E10). Cells transduced with GPI-scFvs (48d) neutra-
lized all 11 HIV-1 pseudotypes with great degree of
potency against HIV-1 pseudotypes expressing envelopes
derived from clades A, B, B’ and E, but less potent
against envelope derived from clade C. Strikingly, cells
Figure 2 Localization of GPI-anchored scFvs in transduced TZM.bl cells. Confocal analysis of mock- or GPI-scFvs (AB65 and X5)-transduced
TZM.bl cells. CtxB: cells were stained with Alexa 555-conjugated cholera toxin B subunit; anti-his: cells were stained with mouse anti-his-tag
antibody followed by Alexa 488-conjugated goat anti-mouse IgG antibody.
Wen et al. Retrovirology 2010, 7:79
http://www.retrovirology.com/content/7/1/79
Page 5 of 18transduced with GPI-scFv (X5) neutralized all 11 HIV-1
pseudotypes with remarkable degree of potency.
We next tested neutralization activity of the secretory
versus the GPI-scFvs against 6 replication competent
HIV-1 strains including two clinical isolates (quasispecies).
F i g u r e3 Ca n d3 Ds h o wm e a na n ds t a n d a r dd e v i a t i o no f
RLA in mock-, secretory and GPI-scFv-transduced cells
infected with these HIV-1 strains. Compared to mock-
transduced cells, cells transduced with all secretory scFvs
did not show significant neutralization activity against any
of these HIV-1 strains tested (Figure 3D). In contrast, cells
transduced with the GPI-scFvs show various degree of
breadth and potency (Figure 3C). Like cells transduced
with GPI-scFv (AB65) control, cells transduced with GPI-
scFv (AB31) did not neutralize any of these HIV-1 strains
tested. Cells transduced with GPI-scFv (AB32 and TG15)
Figure 3 Effect of secretory and GPI scFvs (AB31, AB32, TG15, 4E10, 48d, X5 and AB65) on infection of HIV-1 viruses and pseudotypes.
A. Effect of GPI-scFvs on transduction efficiency of HIV-1 and 10A1 pseudotypes into GPI-scFv-transduced TZM.bl. w/o: parental TZM.bl cells;
*mean and standard deviation of relative luciferase activity. B. Effect of secretory scFvs on transduction efficiency of HIV-1 and 10A1 pseudotypes
into secretory scFv-transduced TZM.bl. w/o: parental TZM.bl cells. C. Effect of GPI-scFvs on wild type HIV-1 infection in GPI-scFv-transduced TZM.
bl. w/o: parental TZM.bl cells. D. Effect of secretory scFvs on wild type HIV-1 infection in secretory scFv-transduced TZM.bl. w/o: parental TZM.bl
cells. Blue color-coated: > or = 50% inhibition; Orange color-coated: > or = 90% inhibition; Red color-coated: >or = 99% inhibition. The
percentage of inhibition was based on the following calculation: (RLA in virus alone to a given transduced cell - RLA in no virus to the same
transduced cell)/(RLA in virus alone to parental cells - RLA in no virus to parental cell).
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low degree of potency; and cells transduced with GPI-scFv
(48d) neutralized 4 viruses including one clinical quasispe-
cies (Bru-3, Bru-Yu2, AD8 and JS-JCD) with various
degree of potency. Interestingly, cells transduced with
GPI-scFv (X5) neutralized all 6 viruses with a remarkable
degree of potency.
Potent inhibition of HIV-1 by GPI-scFv (X5) does not
require additional sCD4
It was previously showed that the scFv (X5) neutralizes
HIV-1 better than the Fab and the whole IgG [40] and
the binding and neutralizing capability of scFv (X5) can
be greatly enhanced by adding soluble extracellular
domains of human CD4 (sCD4) [21,41,42]. We therefore
produced and purified soluble CD4 using the drosophila
S2 expression system (see Additional File 3). We then
tested the effect of sCD4 doses on HIV-1 infection
(Bru-3, Bru-Yu2 and Mj4) and found that at 1 μg/ml or
higher a concentration-dependent inhibition of HIV-1
infection by sCD4 was observed; while below 1 μg/ml
no significant inhibition by sCD4 was observed (Zhou
et al. data not shown). Thus, we chose sCD4 at the con-
centration of 0.3 μg/ml in the subsequent post-CD4
experiments as described before [43].
Figure 4 shows mean and standard deviation of RLA
in mock-, secretory and GPI-scFv-transduced TZM.bl
cells infected with or without HIV-1 Bru-3 or Bru-Yu2
that were pre-incubated with or without sCD4. Pre-
incubation of 400 and 4,000 TCID50 of these two HIV-1
strains with sCD4 greatly enhances inhibition in cells
transduced with secretory scFv (X5); while complete
inhibition was observed in GPI-scFv (X5)-transduced
cells infected with 400 and 4,000 TCID50 of these two
HIV-1 strains, regardless whether the viruses were pre-
incubated with sCD4 or not (Figure 4A-D). Thus, these
results clearly show that while sCD4 enhances inhibition
by secretory scFv (X5); GPI-scFv (X5) exhibits the great-
est potency of inhibition, which is totally independent of
addition of sCD4.
GPI-scFv (X5) confers long-term resistance to HIV-1 in
human CD4
+ T cells
Next, we evaluated if GPI-scFv (X5) would confer the
long-term resistance to HIV-1 in human CD4
+ T cells.
Human CD4
+ cell line CEMss was first transfected with a
retroviral vector expressing human CCR5. After stable
CEMss-CCR5 cells were established, they were further
transduced with secretory and GPI-scFv (X5 and AB65).
The expression of secretory and GPI-scFvs as well as
CD4, CCR5 and CXCR4 in transduced CEMss-CCR5
cells were tested by western blot and immune staining
followed by FACS analysis as described above (see
Additional File 4). Transduced CEMss-CCR5 cells were
then infected with HIV-1 strains Bru-3 and Bru-Yu2 at
multiple of infection of 0.01 as described before [23] and
cultured in the complete DMEM medium for 75 to 105
days, except for cells transduced with secretory scFvs
(AB65 and X5) and infected with Bru-3 (the culture of
these cells was terminated on day 27 post infection). As
s h o w ni nF i g u r e5 Aa n d5 B ,r e p l i c a t i o no fb o t hH I V - 1
Bru-3 and Bru-Yu2 was completely inhibited in cells
transduced with GPI-scFv (X5) throughout the experi-
ments. In contrast, robust replication of HIV-1 Bru-3 and
Bru-Yu2 was observed in cells transduced with secretory
scFv (AB65) and GPI-scFv (AB65) controls. For cells
transduced with secretory scFv (X5) and infected with
HIV-1 Bru-3, HIV-1 replication was as robust as secre-
tory scFv (AB65) and GPI-scFv (AB65) controls. By con-
trast, for cells transduced with secretory scFv (X5) and
infected with HIV-1 Bru-Yu2, robust HIV-1 replication
was observed in the first 6 days and then slowly dropped
to the undetectable level on day 51 and thereafter. These
data demonstrated that GPI-scFv (X5) completely inhi-
bits the infection of HIV-1 Bru-3 and Bru-Yu2. By so
doing it maintains long-term resistance to HIV-1. On the
contrary, secretory scFv (X5) cannot inhibit the infection
and replication of fast replicating HIV-1 like Bru-3, but
can partially inhibits the replication of relatively slow
replicating HIV-1 like Bru-Yu2.
GPI-scFv (X5) blocks HIV-1 envelope-mediated cell-cell
fusion
To evaluate the effect of GPI-scFv (X5) on HIV-1 envel-
ope-mediated cell-cell fusion, the GPI-scFv (X5 and
AB65)-transduced CEMss-CCR5 cells were co-cultured
with 69TiRevEnv cells as previously described [44]. The
latter contains a HIV-1 envelope gene (pLAI3) under a
Tet-off promoter. In the presence of tetracycline, binding
of tetracycline to Tet transactivator (tTA) causes confor-
mational change of tTA, which blocks tTA binding to the
Tet-off promoter and prevents HIV-1 envelope protein
expression; in the absence of tetracycline, tTA binds to
and transactivates the Tet-off promoter resulting in HIV-
1 envelope protein expression (Figure 5C). Co-culturing
GPI-scFv (AB65 and X5)-transduced CEMss-CCR5 cells
with tetracycline-treated 69TiRevEnv cells results in
no cell-cell fusion (Figure 5D and 5E). In contrast, co-
culturing GPI-scFv (AB65)-transduced CEMss-CCR5
cells with tetracycline-untreated 69TiRevEnv cells results
in massive cell-cell fusion (Figure 5F). The fusion begins
after 6 hours and peaks at 20 hours. Importantly, no cell-
cell fusion was observed after 20 hour’s co-culturing
GPI-scFv (X5)-transduced CEMss-CCR5 cells with tetra-
cycline-untreated 69TiRevEnv cells (Figure 5G). The
experiment was repeated twice with similar results. Thus,
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inhibits HIV-1 envelope-mediated cell-cell fusion.
GPI-scFv (X5) blocks the infection of HIV-1captured and
transferred by human DCs
To test the effect of GPI-scFv (X5) on the infection of
HIV-1 captured and transferred by human DCs, mono-
cyte-derived human DCs were incubated with HIV-1
NL4-3. Cells were then washed extensively to remove
free viruses. Infected DCs were then co-cultured with
GPI-scFv (X5 and AB65) transduced CEMss cells for
14 days. HIV-1 replication was measured by HIV-1 p24
assay as described above. As shown Figure 5H, co-
culturing GPI-scFv (AB65)-transduced CEMss cells with
HIV-1 infected monocyte-derived human DCs results
in high p24 expression, indicating robust replication
of HIV-1. In contrast, co-culturing GPI-scFv (X5)-
transduced CEMss cells with HIV-1 infected monocyte-
derived human DCs results in very low level of HIV-1
p24 during the first 4 days and drops off thereafter, indi-
cating inhibition of viral replication. This low level of
HIV-1 replication detected in the coculture of GPI-scFv
(X5)-transduced CEMss cells and HIV-1 infected mono-
cyte-derived human DCs likely reflects slow and covert
HIV-1 replication in monocyte-derived human DCs as
previously reported [45]. Thus, the data clearly demon-
strated that GPI-scFv (X5) can neutralize HIV-1 captured
and transferred by human DCs.
GPI-scFv (X5) does not inhibit transduction by VSV
G pseudotyped HIV-1 vector
Finally we transduced parental CEMss-CCR5 cells and
CEMss-CCR5 [GPI-scFvs (AB65 and X5) secretory scFvs
(AB65 and X5)] with VSV-G pseudotyped HIV-1 vector
expressing enhanced green fluorescent protein (eGFP)
as described before [23]. Because VSV G envelope inter-
acts with lipid moiety in the lipid bilayer of the plasmic
membrane, vectors by pass the requirement of the inter-
action between HIV-1 envelope and its receptor and co-
receptor to enter cells. We found that in all three doses
tested, transducing parental CEMss-CCR5 cells and
CEMss-CCR5 [GPI-scFvs (AB65 and X5) secretory scFvs
Figure 4 Potent inhibition of HIV-1 by GPI-scFv (X5) does not require additional sCD4. sCD4: soluble, extracellular domains of human CD4;
w/o or w/sCD4: with or without pre-incubation of viruses with sCD4; y-axis: mean and standard deviation of relative luciferase activity; mock:
negative control, background relative luciferase activity in uninfected TZM.bl cells. A. Cells infected with 400 TCID50 of HIV-1 Bru-3 with or
without pre-incubation with sCD4; B. Cells infected with 4,000 TCID50 of HIV-1 Bru-3 with or without pre-incubation with sCD4; C. Cells infected
with 400 TCID50 of HIV-1 Bru-Yu2 with or without pre-incubation with sCD4; D. Cells infected with 4,000 TCID50 of HIV-1 Bru-Yu2 with or without
pre-incubation with sCD4.
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similar vector dose-dependent transduction efficiency
and transgene expression (Figure 6). These results
demonstrate that the GPI-scFv (X5) does not inhibit the
VSV G envelope-mediated viral entry, reverse transcrip-
tion, integration, or postintegration protein expression
of HIV-1 vector, indicating that the potent inhibition of
HIV-1 replication and HIV-1 envelope-mediated cell-
cell fusion seen in the GPI-scFv (X5)-transduced CEMss
cells (Figure 5) is HIV-1 envelope-specific and at the
level of viral entry.
Discussion
In this study we demonstrate that by genetically linking
scFvs with GPI-attachment signal scFvs are expressed in
the lipid raft of plasma membrane through a GPI anchor
(Figure 1 and 2). GPI-scFvs, but not secretory scFvs, of
the antibodies (AB32, TG15, 48d and X5) that recognize
transiently-exposed epitopes on HIV-1 envelope spike
neutralize HIV-1 with various degrees of breadth and
potency. Among them, GPI-scFv (X5) exhibits extremely
potent and broad neutralization activity against multiple
clades of HIV-1 (Figures 3). Moreover, we show that
GPI-anchored scFv (4E10) also exhibited more potent
neutralization activity than its secretory counterpart
(Figures 3). Importantly, the expression of GPI-scFv (X5)
on the surface of human CD4
+ T cells confers long-term
resistance to HIV-1 infection, HIV-1 envelope-mediated
cell-cell fusion and the infection of HIV-1 captured and
transferred by human DCs (Figure 5). Thus, targeting
Figure 5 Effect of GPI-scFv (X5) on anti-HIV-1 activity of transduced human CD4
+ T cells. A. GPI-scFv (X5) confers long-term resistance to
HIV-1 Bru-3 in human CD4
+ T cells. sec-AB65: CEMss-CCR5 cells transduced with secretory scFv (AB65); sec-X5: CEMss-CCR5 cells transduced with
secretory scFv (X5); GPI-AB65: CEMss-CCR5 cells transduced with GPI-scFv (AB65); GPI-X5: CEMss-CCR5 cells transduced with GPI-scFv (X5). B. GPI-
scFv (X5) confers long-term resistance to HIV-1 Bru-Yu2 in human CD4
+ T cells. C. Western blot analysis of HIV-1 gp160, gp120 and gp41
expression by anti-HIV-1 gp120 and gp41 antibodies in 69 T1RevEnv cells with or without treatment of tetracycline. Lane 1: 69 T1RevEnv cells
without treatment of tetracycline stained with anti-HIV-1 gp41 antibody; lane 2: 69TiRevEnv cells with treatment of tetracycline stained with anti-
HIV-1 gp41 antibody; lane 3: 69TiRevEnv cells without treatment of tetracycline stained with anti-HIV-1 gp120 antibody; lane 4: 69TiRevEnv cells
with treatment of tetracycline stained with anti-HIV-1 gp120 antibody. D. Cell morphology 20 hours after coculturing tetracycline-treated
69TiRevEnv cells with CEMss-CCR5-GPI-scFv (AB65). E. Cell morphology 20 hours after coculturing tetracycline-untreated 69TiRevEnv cells with
CEMss-CCR5-GPI-scFv (AB65). F. Cell morphology 20 hours after coculturing tetracycline-treated 69TiRevEnv cells with CEMss-CCR5-GPI-scFv (X5).
G. Cell morphology 20 hours after coculturing tetracycline-untreated 69TiRevEnv cells with CEMss-CCR5-GPI-scFv (X5). H. GPI-scFv (X5) blocks the
infection of HIV-1captured and transferred by human DCs. GPI-X5: co-culturing infected human DC with CEMss cells transduced with GPI-scFv
(X5); GPI-AB65: co-culturing infected human DC with CEMss cells-transduced with GPI-scFv (AB65).
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membranes of HIV-1 susceptible cells through a GPI
anchor is an effective way to capture transiently exposed
neutralization epitopes of HIV-1 envelope spike. GPI-
scFv (X5) with such remarkable breadth and potency
should have a potential to be developed into an anti-viral
agent for HIV-1 prevention and therapy. For example,
similar to those recently reported by DiGiusto et al. [46],
GPI-scFv (X5) could be delivered into hematopoietic pro-
genitor cells of HIV-1 patients ex vivo through lentiviral
vector and transduced cells could then be transfused to
the patients. However, in order to achieve clinical efficacy
with this gene therapy approach, many hurdles, such as
low degree of transduction efficiency and engraftment,
difficulty in maintenance of self renewal as well as hema-
topoietic linage cell differentiation of transduced
Figure 6 eGFP expression in parental CEMss-CCR5 cells and CEMss-CCR5 expressing GPI-scFvs (AB65 and X5) and secretory scFvs
(AB65 and X5) transduced with VSV-G pseudotyped HIV-1 vector. A. % of eGFP positive cells; B. MFI.
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expression, potential insertion mutagenesis, have to be
overcome.
Interestingly, although their level of expression on the
cell surface is similar (Figure 1C), 6 anti-HIV-1 gp120
or gp41 GPI-scFvs tested in this study display the wide
spectrum of breadth and potency against 11 HIV-1
pseudotypes and 6 wild type HIV-1 strains tested (Fig-
u r e3 ) .A to n ee n do ft h es p e c t r u m ,G P I - s c F v( A B 3 1 )
does not show significant neutralization activity against
any of these HIV-1 viruses; while on the other end of
the spectrum, GPI-scFv (X5) neutralizes all HIV-1
viruses with remarkable degree of potency. Between
these two extremes, GPI-scFvs (AB32, TG15, 4E10 and
48d) show a progressive increase of breadth and
potency. Furthermore, although they both recognize
CD4-induced epitopes, GPI-scFv (48d) and GPI-scFv
(X5) show different potency against HIV-1 strains from
clade C, but similar potency against HIV-1 strains from
clades A, B, B’ and E. Thus these results strongly sug-
gest that the breadth and potency of a given GPI-scFv
does not just depend on local concentration, but it is
dependent on the fine specificity of the transiently-
exposed neutralization epitope it targets.
In this study, we also show that potent inhibition of
HIV-1 by GPI-scFv (X5) does not depend on additional
sCD4 (see Figure 4). We believe that this likely has
something to do with the X5 epitope. The X5 epitope
resides within a conserved region (amino acid residues
417 to 434) of the gp120 core, particularly in the vicinity
of amino acid residues at positions 423 and 432, which
is in the proximity of the CD4 and coreceptor binding
sites [35]. According to the crystal structure of gp120
core with or without sCD4 [41,42] as well as crystal
structure of a complex containing V3-containing gp120
core, the CD4 receptor and the Fab (X5) [47], the
amino acid residues 417 to 434 reside in b19, b20 and
b21 of the gp120 core. The b20 and the b21 form an
anti-parallel b sheet. Without adding sCD4, b19 and
b20/b21 are away from each other, the b19 is covered
by V3 loop and the b20/b21 is partially covered by V1/
V2 loop. Because of this, secretory scFv (X5) does not
have neutralization activity. In contrast, adding sCD4
induces a CD4-induced conformation of gp120. In this
conformation, the b19 and the b20/b21 are not only
totally exposed, but also become close to each other
[42]. As a result, adding sCD4 greatly enhances neutrali-
zation activity of secretory scFv (X5) (Figure 4). How-
ever, it is very plausible that even in the presence of
sCD4 CD4-induced conformation of the HIV-1 spike is
transient, so that secretory scFv (X5) may not be able to
catch all X5 epitopes on the spikes of the virion. As a
result, neutralization activity is not optimal. GPI-scFv
(X5), on the other hand, due to its lipid raft location
and local concentration, may have much better access
to its transiently-exposed neutralization epitope upon
interaction of CD4 with the native envelope spike. Here
CD4, a raft-associated protein, resides in the lipid raft of
the plasma membrane of target cells, which is the same
location as GPI-scFv (X5). As a result, GPI-scFv (X5)
may quickly and efficiently capture the CD4-induced
neutralization epitope and completely block the envel-
ope spike in a pre-fusion intermediate step. However,
the underlying mechanism of great potency of GPI-scFv
(X5) remains to be elucidated.
There are at least two implications of the findings in
this study. First, given the promising results obtained in
this study, it is plausible to develop GPI-scFvs into a
standard approach for identifying antibodies that recog-
nize transiently-exposed epitopes on HIV-1 envelope
spike. It is conceivable that for many anti-HIV-1 gp120
and gp41 antibodies that have no or poor neutralization
activity against native envelope spikes, GPI-scFvs of
these antibodies can be made and tested against a panel
of different HIV-1 variants and subtypes. If some of
these GPI-scFvs exhibit good neutralization activity, one
can then use these GPI-scFvs in combination with
epitope mapping methods (such as alanine-scanning
mutants) to identify transiently-exposed neutralization
epitopes in the HIV-1 envelope spike. Second, it is also
plausible that GPI-scFvs be used to identify antibodies
that recognize transiently-exposed epitopes and then to
identify transiently-exposed neutralization epitopes of
other viruses, particularly of those enveloped viruses
whose entry into target cells depend on lipid raft and
the interaction of those envelope glycoprotein with
receptor results in conformational changes. It has been
shown that glycoproteins of influenza virus, murine leu-
kemia virus, measles virus and Ebola virus are associated
with the lipid raft of plasma membrane [48-52]. The
entry of many enveloped viruses, such as vaccinia virus
[53], severe acute respiratory syndrome-coronavirus
[54], duck hepatitis B virus [55], murine leukemia virus
[56] and herpes simplex virus [57], requires cholesterol
in the target cell membrane. Therefore, development of
G P I - s c F v st h a ta r ed e r i v e df r o ma n t i b o d i e st h a tr e c o g -
nize transiently-exposed epitopes in glycoproteins of
these viruses may also be an effective way to inhibit cell
entry of these viruses.
Conclusions
GPI anchored scFvs that recognize different transiently-
exposed epitopes on HIV-1 envelope spike exhibit var-
ious degrees of breadth and potency. Among them,
GPI-scFv (X5) that recognizes the epitope near the CD4
binding site and coreceptor (CCR5) binding site, exhib-
ited greatest potency and breadth against multiclades of
HIV-1 strains. Our data therefore demonstrate that
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antibodies that recognize transiently-exposed epitopes in
glycoproteins spike of HIV and other enveloped viruses.
GPI-scFvs derived from such antibodies could be an
effective way to inhibit cell entry of HIV and other
enveloped viruses.
Methods
Viruses and cell lines
Proviral plasmids pBru-3, pBru-Yu2, pAD8, pNL4-3 and
pMj4 were obtained from the NIH AIDS Research and
Reference Reagent Program( A R R R P ,G e r m a n t o w n ,
MD). Infectious virus stocks of HIV-1 Bru-3 and NL4-3
(X4 tropic, subtype B), Bru-Yu2, and AD8 (R5 tropic,
subtype B) and Mj4 (R5 tropic, subtype C) were pro-
duced by transfecting into 293T cells using a calcium
phosphate precipitation or a Fugene-6 reagent method
(Roche Diagnostics, Mannheim, Germany). Virus stocks
were then propagated by infecting phytohemagglutinin
(PHA)-stimulated human peripheral blood mononuclear
cells (PBMCs) with these infectious clones as described
before [24]. Primary HIV-1 isolates RJ407 and JS-JCD
were generated by infecting PHA-stimulated human
PBMCs with plasmas of two subjects in a cohort of indi-
viduals who was recruited for a study of HIV-1 fitness.
Informed consent was obtained from participants in
accordance with the Institutional Review Boards of the
Huashan Hospital, Shanghai, China. All virus stocks
(Bru-3, NL4-3, Bru-Yu2, AD8, Mj4, RJ407, and JS-JCD)
were stored in aliquots at a -80°C degree freezer. The
titers of the stocks were determined by end-point titra-
tion on TZM.bl cells (see below).
The packaging cell line 293T was purchased from Invi-
trogen Life Technologies (San Diego, CA) and main-
tained in complete DMEM medium [i.e. high glucose
DMEM supplemented with 10% FBS, 2 mM L-glutamine,
1 mM sodium pyruvate, penicillin (100 U/ml), streptomy-
cin (100 μg/ml)] plus G418 (500 μg/ml) (Invitrogen Life
Technologies). Human CD4
+ Tc e l ll i n eC E M s sw a s
obtained from Dr. Jon Allan at the Department of Virol-
ogy and Immunology, the Southwest Foundation for Bio-
medical Research, San Antonio, TX. TZM.bl and
69Tirev/env cells were obtained from NIH ARRRP, as
contributed by J. Kappes and X. Wu [58,59] and H. Yu
[44], respectively. CEMss cells and TZM.bl cells were
maintained in complete DMEM. 69TiRev/Env cells were
maintained in complete DMEM plus 0.2 mg/ml G418.
Drosophila Schneider 2 (S2) cells were purchased from
Invitrogen Life Technologies and maintained in 75 cm
flask (Corning) at the cell density between 0.2 to 2 ×
10
6 cells per ml in the Express FIVE® SFM medium
(Invitrogen Life Technologies) supplemented with 10%
FBS, 100 U/ml penicillin, 100 U/ml streptomycin and
100 mg/L L-glutamine at 28°C without additional CO2.
Gene construction
To construct the scFv/IgG3 hinge/his-tag/DAF, a 143-bp
DNA fragment containing a 8-bp sequence of 3’end of
human IgG3 hinge region, a 123-bp sequence encoding a
6 x his tag, the C-terminal 34 amino acid residues of
DAF [37] and a stop codon, and a 12-bp sequence of a
Sal I site and additional 6 bp were linked by a recursive
PCR [60]. Another DNA fragment containing a 12-bp
sequence of a Bgl II site and additional 6 bp, a sequence
encoding the signal peptide, anti-HIV-1 gp41 scFv
(TG15) and 11 residues of human IgG3 hinge region, and
an 8-bp sequence of the 5’end of the his tag was ampli-
fied by PCR using previously generated pLNCX-TCR-m-
scFv as a template [23]. These two fragments were
designed in such a way that there were 16 nucleotides
overlapping between the 3’end of scFv/hinge and 5’end of
his tag/DAF fragments. In addition, an Xba I site was
inserted between the sequences of the signal peptide and
the scFv and a Xma I site was inserted between the
sequences of scFv and IgG3 hinge region to facilitate
cloning process of other scFvs (see below). The whole
fragment encoding the entire scFv(TG15)/hinge/his-tag/
DAF was then generated by an overlapping PCR. The
amplified cDNA was then ligated in a TA vector system
(Invitrogen Life Technologies) for sequence analysis.
cDNA containing the correct scFv(TG15)/hinge/his-tag/
DAF was cloned into the Bam HI and Sal I sites of lenti-
viral transfer vector pRRLsin-18.PPT.hPGK.Wpre [61].
The resulting lentiviral transfer construct was designated
as pRRL-scFv(TG15)/hinge/his-tag/DAF (Figure 1A).
To construct genes encoding scFvs (AB31, AB32, 4E10,
X5 and 48d), overlapping primers for the recursive PCR
were synthesized according to the published sequences
[34,62]. The end primers of recursive PCR were designed
in such a way that the Xba I and the Xma I sites were
introduced at 5’ and 3’ ends of the scFv genes, respectively.
The gene encoding scFv (AB65) was derived from the VH
and VL fragments of a human monoclonal antibody gen-
erated from convalescent plasma of H5N1 avian influenza
virus infected patient in our laboratory. The amplified
genes encoding scFvs were ligated in a TA vector system
for sequencing. cDNA containing the correct scFvs were
then inserted into the Xba I and Xma I sites of pRRL-scFv
(TG15)/hinge/his-tag/DAF. The resulting lentiviral trans-
fer constructs were designated as pRRL-scFv(AB31, AB32,
4E10, X5, 48d and AB65)/hinge/his-tag/DAF, respectively
(see Figure 1A and Additional File 1).
To construct a secretory form of the scFvs, a gene
encoding sequence containing the signal peptide, scFv
(TG15), IgG3 hinge, his-tag and a stop codon was first
amplified by PCR using the pRRL-scFv(TG15)/hinge/his-
tag/DAF as a template. The correct sequence was inserted
into the Bam HI and the Sal I sites of pRRL-scFv(TG15)/
hinge/his-tag/DAF to generate the lentiviral transfer
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sequences encoding each of the other scFvs (AB31, AB32,
X5, 4E10, 48d and AB65) were inserted into the Xba I and
the Xma I sites of pRRL-scFv(TG15)/hinge/his-tag. The
resulting lentiviral transfer constructs were designated as
pRRL-scFv(AB31, AB32, X5, 4E10, 48d and AB65)/hinge/
his-tag, respectively (Figure 1A and Additional File 1).
To generate genes encoding soluble human CD4 pro-
tein to be produced by Drosophila S2 cells, a gene
encoding extracellular domain of the human CD4 pro-
tein with a his-tag at its C-terminus was PCR-amplified
using total RNA isolated from CEMss cells as a template
and ligated into the TA vector as described above. The
correct gene sequence was then inserted into Bgl II and
BstB I sites of an inducible S2 expression vector pMT-
bip/V5-His (Invitrogen). The resulting plasmid was
designated as pMT-bip-sCD4.
The gene encoding retroviral envelope 10A1 was PCR-
amplified from the packaging cell line PT67 originally
developed in Dusty Miller’s laboratory [39]. The gene
encoding the HIV-1 envelope Yu2 was PCR-amplified
from proviral DNA (Bru-Yu2) (see above). The correct
sequences (10A1 and Yu2) were then cloned into the
Sal I and the Bam HI sites of CMV/R expression vector
[38]. The resulting plasmids were designated as CMV/
R-env (10A1) and CMV/R-env (Yu2), respectively.
The gene encoding human CCR5 was PCR amplified
using total RNA isolated from human PBMCs as a tem-
plate and ligated into the TA vector as described above.
The correct gene sequence was then inserted into Bam
HI and Sal I sites of a lentiviral transfer vector pRRLsin-
18.PPT.hPGK.Wpre. The resulting lentiviral transfer
construct was designated as pRRL-CCR5.
Generation of recombinant lentiviral vectors
Recombinant lentiviral vectors were generated as
described before [23]. Briefly, 4 × 10
6 293T cells were
seeded onto P-100 dish in 10 ml complete DMEM.
After overnight culture, cells were co-transfected with
20 μg transfer construct (one of pRRL-scFv/hinge/his-
tag/DAFs or pRRL-scFv/hinge/his-tags as well as pRRL-
CCR5), 10 μg packaging construct encoding HIV-1 gag/
pol (pLP1), 7.5 μg plasmids encoding VSV-G envelope
(pLP/VSVG) and 7.5 μg HIV-1 rev protein (pLP2) (Invi-
trogen) using a calcium phosphate precipitation method.
Sixteen hours later, culture supernatants were removed
and replaced with fresh complete DMEM plus 1 mM
sodium butyrate (Sigma). Eight hours later, supernatants
were again removed and replaced with fresh DMEM
plus 4% FBS. After another 20 hours, the culture super-
natants were harvested and concentrated by ultra-centri-
fugation as described before [38]. The vector pellets
were resuspended in a small volume of DMEM and
stored in aliquots at -80°C degree freezer. Vector titers
were determined as we previously described [23]. The
amount of HIV-1 gag p24 in concentrated vector stocks
was determined by ELISA (see below).
Generation of stable CEMss-CCR5 cells
To generate CEMss-CCR5 cells, 1 × 10
5 CEMss cells
and 2 × 10
6 TU of recombinant lentiviral vector expres-
sing human CCR5 were added onto 24-well tissue cul-
ture plate in the presence of 8 μg/ml of polybrene
(Sigma). Twenty four hours later cells were extensively
washed and cultured in complete DMEM. The expres-
sion of CCR5 was measured by FACS analyses.
Generation of soluble CD4 (sCD4) by drosophila S2 cells
Soluble CD4 were generated according to the manufac-
turer’si n s t r u c t i o n .B r i e f l y ,2×1 0
6 S2 cells were seeded
onto each well of 6-well plate in 3 ml Express FIVE®
SFM medium. After overnight culture, cells were co-
transfected with 19 μgp M T - s C D 4a n d1μgp C o B l a s t
(Invitrogen life Technologies) using a calcium phosphate
precipitation method. Forty eight hours later, 25 μg/ml
blasticidin were added into medium to select stably
cotransfected cell lines and followed by limiting dilution
assay to select stable cell clones.
To produce sCD4, stable clones were induced with
5 μg/ml CdCl2 for 3 to 5 days. Soluble CD4 in superna-
tants were harvested and purified by Ni-NTA column
(Invitrogen) according to manufacturer’s instruction.
The amount of proteins was quantified by BCA assay
(Pierce) and the purity of proteins was determined by
12% SDS/PAGE followed by Coomassie blue staining.
Generation of stable cell lines expressing secretory and
GPI-scFvs
To transduce CEMss and CEMss-CCR5 cells, 1 × 10
5
CEMss or CEMss-CCR5 cells and 2 × 10
6 TU of one of
the lentiviral vectors containing pRRL-scFv (X5 or
AB65)/hinge/his-tag/DAF or pRRL-scFv(X5 or AB65)/
hinge/his-tag were added onto 24-well tissue culture
plate in the presence of 8 μg/ml of polybrene (Sigma).
Twenty four hours later cells were extensively washed
and cultured in complete DMEM. To transduce TZM.bl
cells, 5 × 10
4 TMZ.bl cells per well were seeded onto 24
well plate. After overnight culture, 2 × 10
6 TU of one of
lentiviral vectors containing pRRL-scFv (TG15, AB31,
AB32, 4E10, X5, 48d or AB65)/hinge/his-tag/DAF or
pRRL-scFv (TG15, AB31, AB32, 4E10, X5, 48d or
AB65)/hinge/his-tag were added onto 24-well tissue cul-
ture plate in the presence of 8 μg/ml of polybrene.
Twenty four hours later cells were extensively washed
and cultured in complete DMEM. Expression of scFv/
hinge/his-tag/DAF constructs was measured by FACS
and western blot analyses and expression of scFv/hinge/
his-tag was measured by western blot analysis (see
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transduction, over 98% cells express transgenes (data
not shown). After transduced cells were generated, cells
were continuously cultured in complete DMEM and
split every 3 or 4 days. Periodically, expression of trans-
genes was measured. We found that the level of trans-
gene expression was very stable in the transduced cell
lines (data not shown).
FACS analysis
To study cell surface expression of scFv/hinge/his-tag/
DAF, 2 × 10
5 mock- and scFv (TG15, AB31, AB32, 4E10,
X5, 48d and AB65)/hinge/his-tag/DAF-transduced TZM.
bl cells, mock- and scFv (X5 and AB65)/hinge/his-tag/
DAF-transduced CEMss-CCR5 cells were incubated with
a mouse anti-his-tag antibody (Sigma) for 45 min on ice.
Cells then were washed twice with FACS buffer (PBS
containing 1% BSA and 0.02% NaN3) and stained with
PE-conjugated goat anti-mouse IgG antibody (Sigma) for
another 45 min on ice. Cells then were washed twice
with FACS buffer and fixed with 1% formaldehyde in 0.5
ml of FACS buffer. FACS analysis was performed on a
FACScan (Becton Dickinson, Mountain View, CA).
To determine whether the expression of scFv (TG15,
AB31, AB32, X5, 48d and AB65)/hinge/his-tag/DAF is
truly through a GPI anchor, 2 × 10
5 mock- and scFv/
hinge/his-tag/DAF-transduced TMZ.bl and CEMss-
CCR5 cells were first incubated with or without 3 μg/ml
PI-PLC (Prozyme, San Leandro, CA, USA) in DMEM
containing 1% FBS at 37°C for 30 min. After the incuba-
tion, cells were washed twice to remove remaining
PI-PLC and then stained with a mouse anti-his-tag anti-
body as described above.
Western blot analysis
1×10
6 cells [TZM.bl-GPI-scFvs (AB65, TG15, AB31,
AB32, X5 and 48d), TZM.bl-scFvs (AB65, TG15, AB31,
AB32, X5 and 48d), CEMss-R5-GPI-scFvs(AB65 and
X5) and CEMss-R5-scFvs(AB65 and X5)] were grown in
the DMEM plus 1% FBS on the 12-well plate for 24
hours. Cells and supernatant were harvested respec-
tively. Cells were lysed by lysis buffer (100 mM Tris-
HCl, pH8.0, 1% NP40) in the presence of protease inhi-
bitor cocktail (Calbiochem). Proteins in supernatant
were precipitated by TCA and dissolved in the equal
volume of lysis buffer that to lysed cell pellet. Samples
were detected by mouse anti-His tag antibody (Sigma)
and mouse anti human beta-tubulin antibody as a refer-
ence control.
Generation of pseudotypes of HIV-1 vector and a single-
cycle infectivity assay
To generate pseudotypes with the HIV-1 vector, 4 × 10
6
293T packaging cells were co-transfected with 10 μgo f
HIV-1-luciferase transfer vector [38] and 10 μgo fD N A
plasmid encoding one of HIV-1 envelopes (Q168, AD8,
ADA, JR-FL, Yu2, HxBc2, consensus B, Mj4, CN054,
CNE8, CNE11 or CNE17) or control retroviral envelope
10A1 using a calcium phosphate precipitation method
(see above). DNA plasmids encoding HIV-1 envelopes
Q168, AD8, ADA, JR-FL, HxBc2 and Mj4 were obtained
from ARRRP. DNA plasmid encoding consensus B was a
generous gift of Dr. B.H. Hahn at the University of Ala-
bama. DNA plasmids encoding CNE8, CNE11 or CNE17
were obtained from Dr. Linqi Zhang at the Tsinghua
University. HIV-1 envelope Q168 is derived from a R5
tropic clade A virus [63]. HIV-1 envelopes AD8, ADA,
JR-FL, Yu2 are derived from R5 tropic clade B viruses
[64-67]. HIV-1 envelope HxBc2 is derived from a X4
tropic clade B virus [68]. HIV-1 envelope consensus B is
an artificial envelope originally generated in Dr. Hahn’s
laboratory [69]. HIV-1 envelopes Mj4 is derived from R5
tropic clade C viruses [70]. HIV-1 envelope CNE8 is
derived from a R5 tropic clade CRF01_AE virus. HIV-1
envelope CNE11 is derived from a R5 tropic clade
B’ virus. HIV-1 envelope CNE17 is derived from a R5
tropic clade CRF07_B’C virus (Zhang et al. unpublished
data). The pseudotype-containing supernatants were
harvested and stored in aliquots at -80°C degree freezer.
The amount of HIV-1 p24 in collected supernatants was
measured by ELISA.
In a single-cycle assay to measure the infectivity of pseu-
dotypes, 10,000 Mock-, scFv/hinge/his-tag-, scFv/hinge/
his-tag/DAF-transduced TZM.bl cells were transduced
with HIV-1 pseudotype-containing supernatants equiva-
lent to relative luciferase activity 300,000 to 1,000,000
overnight. Cells were then washed twice with PBS and cul-
tured in complete DMEM medium for 2 days. Cells were
then washed once with PBS and lysed in 100 μlo fl y s i s
buffer. Luciferase activity in 50 μl of cell suspensions was
measured by a BrightGlo Luciferase assay according to the
manufacturer’s instruction (Promega).
HIV-1 infection and luciferase and p24 assays
Mock-, scFv/hinge/his-tag-, scFv/hinge/his-tag/DAF-
transduced TMZ.bl cells at 5,000 cells per well were
seeded onto 96-well plate. After the overnight culture,
cells were infected with HIV-1 strains Bru-3, Bru-YU2,
AD8, Mj4, RJ407 and JS-JCD (100 to 200 TCID50)i na
final volume of 0.5 ml overnight. Cells were then
washed three times with HBSS and resuspended in 2 ml
of the complete DMEM medium and incubated at 37°C
for 2 days. Infectivity of HIV-1 was determined by a
BrightGlo Luciferase assay (see above).
To test the effect of sCD4 on anti-HIV potency of
secretory and GPI-anchored scFvs (X5), parental TZM.
bl cells, TZM.bl-scFv (X5) and TZM.bl-GPI-scFv (X5)
(5,000 cells per well) were seeded onto 96-well plate and
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HIV-1 Bru-3 and Bru-Yu2 were first mixed with or
without pre-determined 0.3 μg/ml of sCD4 at 37°C for
15 minutes. Viruses with or without sCD4 were then
added onto parental TZM.bl cells, TZM.bl-scFv (X5)
and TZM.bl-GPI-scFv (X5) cells. After 2 days, infectivity
of HIV-1 was determined by BrightGlo Luciferase assay
(see above).
Long term culture of HIV-1 infected cells
1×10
6 CEMss-CCR5 cells transduced with GPI-scFvs (X5
or AB65) and secretory scFvs (X5 or AB65) were infected
with HIV-1 strains Bru-3 and Bru-Yu2 (200 TCID50)i na
final volume of 0.5 ml overnight. Cells were then exten-
sively washed with HBSS, resuspended in 6 ml of com-
plete DMEM and cultured for 3 to 15 weeks. Every
3 days, 4.5 ml of cell suspensions were harvested and
replaced with the fresh medium. The supernatants were
then collected. HIV-1 p24 in the supernatants were mea-
sured by ELISA (Beckman Coulter) according to the
manufacturer’s instruction.
Cell-cell fusion experiment
69TiRev/Env cells (1×10
5 per well) with or without 2
μg/ml tetracycline treatment were grown on 12-well
plate at 37°C overnight. CEMss-GPI-scFvs (AB65 or X5)
(2×10
5) were then added onto 69TiRev/Env cells. Cell-
cell fusion was monitored under the light microscopy at
various time intervals. When fusion process reached
peak at 20 hours, the results were recorded by CCD
digital camera (Leica DM IRB).
Ex vivo generation of human DC
Peripheral blood was obtained from healthy donors at
the Gulf Coast Regional Blood Center, Houston, Texas.
Peripheral blood mononuclear cells (PBMCs) were iso-
lated using Ficoll density gradient centrifugation as
described before [71]. To isolate CD14
+ monocytes, the
anti-CD14 microbeads and miniMACS system were
used according to manufacturer’si n s t r u c t i o n s( M i l t e n y i
Biotech, Auburn, CA). Briefly, 10
8 PBMCs were resus-
pended in 800 μl of binding buffer (PBS containing 0.5%
BSA and 2 mM EDTA). 200 μlo fM A C SC D 1 4
microbeads were added, mixed and incubated at 4°C for
15 minutes. The cell-bead mixture was then washed
once with binding buffer and resuspended in 1 ml of
fresh binding buffer. CD14
+ cells were positively selected
using an MS+/RS
+ column tip. The isolated cells were
washed once with complete RPMI and cultured in the
complete RPMI supplemented with GM-CSF (1000 U/
ml) and IL-4 (1000 U/ml) (R & D System, Minneapolis,
MN) for 7 days to generate immature DCs as described
before [72]. The expression of DC-SIGN on the cell sur-
face of immature DCs was measured by anti-DC-SIGN
antibody staining followed by FACS analysis as
described before [23].
Capture and transfer assay with human DCs
DCs (10
5 per well) were seeded in triplicates in a 96 well
U-bottom plate and incubated with 100 TCID50 of NL4-
3 in a total volume of 200 μl at 37°C and 5% CO2 for 4
hours. Cells were then washed three times with PBS to
remove cell-free virus and resuspended in 2 ml of com-
plete RPMI into wells of 24-well plate with or without
adding 1.5 × 10
5 CEMss-GPI-scFvs (AB65 and X5) cells.
Cells were continued to be cultured for 14 days. Every 3
or 4 days, medium was removed from each well and
replaced with fresh complete medium. HIV-1 p24 in the
supernatants was measured by ELISA as described above.
Immunofluorescent staining and confocal analysis
Parental and TZM.bl-GPI-scFvs (AB65 and X5) cells
were seeded (5,000 cells per well) onto the Lab-Tek
chamber slide (Nalge Nunc International, Rochester, NY)
and incubated at 37°C 5% CO2 for 2 days. Cells were
then washed twice with 500 μl PBS and fixed by fixation
buffer (4% formaldehyde in PBS plus 1%BSA) for 15 min.
Cells were washed twice with 500 μl PBS and blocked
with blockage buffer (5% goat serum in PBS plus 1%BSA)
for 1 hour. Cells were stained with Alexa 555 conjugated
CtxB (Invitrogen Life Technologies) at 4°C for 45 min.
After washed 3 times with PBS, cells stained with mouse
anti-his-tag antibody (Sigma) at 4°C for 45 min, then
stained with Alexa 488-conjugated goat anti-mouse IgG
antibody (Invitrogen) at 4°C. After cells were washed 3
times with PBS, cells were stained with 4’,6-diamidino-2-
phenylindole (DAPI) in permeabilization buffer (blockage
buffer plus 0.5% saponin) for 5 min. The slides were
mounted before being analyzed under confocal fluores-
cent microscope (Zeiss Model LSM 510).
Additional material
Additional file 1: Supplementary Figure 1. Expression of GPI-scFvs
(AB65 and X5) in transduced TZM.bl cells. a. Schematic diagram of
the lentiviral vectors pRRL-scFv(4E10)/hinge/his-tag/DAF and pRRL-scFv
(4E10)/hinge/his-tag. b. FACS analysis of cell surface expression of scFv/
hinge/histag/DAF in mock-, scFvs (AB65, X5 and 4E10)/hinge/histag/DAF.
Additional file 2: Supplementary Figure 2. Effect of transgenes on
cell surface of expression of HIV-1 receptor and co-receptors in
TZM.bl cells. a. Cell surface expression of CD4, CCR5 and CXCR4 of
parental TZM.bl cells (mock) and TZM.bl cells transduced with lentiviral
vectors expressing GPI-scFvs (AB31, AB32, TG15, 48d, X5 and AB65). b.
Cell surface expression of CD4, CCR5 and CXCR4 of parental TZM.bl cells
(mock) and TZM.bl cells transduced with lentiviral vectors expressing
secretory scFvs (AB31, AB32, TG15, 48d, X5 and AB65). c. Side by side
comparison of cell surface expression of CD4, CCR5 and CXCR4 of
parental TZM.bl cells (mock) and TZM.bl cells transduced with lentiviral
vectors expressing GPI-scFvs (AB65, X5 and 4E10) or secretory scFvs
(AB65, X5 and 4E10).
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Page 15 of 18Additional file 3: Supplementary Figure 3. Expression of soluble
CD4. Coomassie blue staining of purified soluble CD4 by transfected
drosophila S2 cells and separated by 12% SDS/PAGE.
Additional file 4: Supplementary Figure 4. Expression of secretory
and GPI-scFvs (AB65 and X5) in transduced CEMss-CCR5 cells. a.
Western blot analysis of expression of scFvs (X5 and AB65) in CEMss-
CCR5 cells transduced with lentiviral vectors pRRL-scFv/hinge/his-tag/DAF
(AB65 and X5) and pRRL-scFv/hinge/his-tag (AB65 and X5). GPI-scFv: GPI-
anchored scFv; Sec scFv: secretory scFv; anti-his: anti-his-tag antibody. b.
FACS analysis of cell surface expression of scFv/hinge/histag/DAF in
mock-, scFvs (X5 and AB65)/hinge/histag/DAF- or m-scFv(TG15)-
transduced CEMss-CCR5 cells with or without PI-PLC treatment. c. Cell
surface expression of CD4, CCR5 and CXCR4 of parental CEMss-CCR5 cells
(mock) and CEMss-CCR5 cells transduced with lentiviral vectors
expressing GPI-scFvs (X5 and AB65) and secretory scFvs (X5 and AB65).
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